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CorrespondenceIn a recent article, Cerletti et al. (2008) 
report the preparation of a new, highly 
myogenic subset of skeletal muscle sat-
ellite cells that bestows functional ben-
efits when grafted into the dystrophic 
muscles of mdx mice. Cerletti et al. (2008) 
used FACS to sort these skeletal muscle 
precursors (SMPs), defined by a number 
of antigenic markers, from the popula-
tion of cells adhering to freshly isolated 
muscle fibers of mice that express green 
fluorescent protein (GFP) as a genetic 
label. These SMPs were then grafted into 
the muscles of normal mice damaged by 
injection of a toxin or into the muscles 
of dystrophic mdx mice, which exhibit 
spontaneous muscle degeneration.
Although the authors do indeed show 
that SMPs contribute strongly to regen-
eration when grafted into myotoxin-
damaged or dystrophic mouse muscles, 
their claim that SMPs are a discrete 
stem cell subset of the muscle satellite 
cell population is, in my view, problem-
atic. SMPs appear to share most of their 
markers with the major portion of the 
satellite cell population, and Cerletti et 
al. do not clearly demonstrate that they 
are functionally superior to or distinct 
from the general satellite cell population. 
In addition, it is not clear whether the 
SMPs are distinct from the muscle satel-
lite cell population, reported in a previ-
ous study (Montarras et al., 2005), that 
were isolated on the basis of Pax3-GFP 
expression or CD34 expression in com-
bination with forward- and side-scatter 
parameters.
Of greater concern is the claim by 
Cerletti et al. of functional normaliza-
tion of successfully grafted muscles 
(see Figure 5 and Table S1 of Cerletti et 
al., 2008). Two functional parameters of 
muscle physiology were analyzed (the 
peak tetanic force and the area under 
the force/time curve), averaged over a 
sequence of maximal stimuli. Both sets 
of measurements were normalized to 
muscle size and so should reflect an 
intrinsic functional quality of the muscles. 
But the values plotted against % muscle 
fibers positive for GFP were the ratios 
of values for cell-injected muscle and 
contralateral medium-injected muscle 
(Figures 5B and 5C). Such pairing can be 
of value when the parameters are con-
sistent between contralateral muscles 
within the same animal but are expected 
to vary between animals. Inspection of 
the raw data (Table S1 of Cerletti et al., 
2008) does not point to such a situation 
nor is any supporting evidence cited.
Superficially, the plots in Figures 5B and 
5C of Cerletti et al. (2008) look impressive, 
with strong correlations between %GFP-
positive muscle fibers and the ratio mea-
surements of muscle strength. It is inferred 
that muscles containing the highest pro-
portion of GFP-expressing myofibers are 
stronger, exhibiting “up to 5.5-fold greater 
force production compared to mock-
transplanted muscles.” This implies a 
far larger difference between dystrophic 
mdx muscle and normal muscle than has 
been reported previously and encourages 
inspection of the raw data. Averages of 
normalized peak tension—illustrated here 
in Figure S1A (available online) as a bar 
plot of each contralateral muscle pair and 
of the ratio between them—show that the 
muscles containing the highest propor-
tion of GFP-positive fibers are not nota-
bly stronger and that the muscle-tension 
traces in Figure 5A are not necessarily 
representative. In fact, the mean absolute 
values for the two functional parameters 
are marginally higher in the sham-injected 
(25.9) than in the cell-injected (24.25) 
muscles, arguing against any significant 
deleterious effect of the sham injections 
or beneficial effect of the cell injections. 
What is notable is that those muscles 
containing the highest proportion of GFP-
positive fibers have the highest ratios of 
peak tension, not because they are par-
ticularly strong but because the sham-
injected contralateral muscles are unusu-
ally weak. This is most conspicuous in 
the case of the pair of muscles at 87.5% 
GFP that show the 5.5-fold ratio. Here, the 
sham-injected control is the second weak-
est in the series, whereas the strength of 
the cell-injected contralateral muscle is 
unexceptional. These data would better 
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graft in normal muscle weakens the con-
tralateral muscle by 80%. To extend this 
argument, it should be remembered that 
the two components of a ratio each carry 
equal weight. When plotted against its 
two components, the ratio of cell-injected 
to sham-injected peak tension clearly 
shows a stronger inverse relationship 
with strength in the sham-injected con-
trol muscle than its positive association 
with strength in the treated muscle (see 
Figure S1B). This generalizes the conclu-
sion that high ratios between the muscle 
pairs expressing high GFP levels in the 
treated muscle are largely attributable to 
the low values in the sham-grafted control 
muscle. The other functional parameter 
considered by the authors, the average 
area under the curve, shares these same 
problems.
Hence, I question two of the central 
claims in the Cerletti et al. (2008) article. 
I contend that the data presented sup-
port neither the notion that a new class of 
myogenic cell has been isolated nor that 
successful grafts of this new cell into mus-
cles of dystrophic mdx mice leads to near 
normalization of muscle function. From 
previous investigations into the effects of 
normal myoblast grafts into injured mus-
cle, we would expect some physiological 
improvement associated with high levels 
of engraftment within the cell-injected 
muscles (Arcila et al., 1997; Irintchev et al., 
1997). Visual inspection of the raw data, 
as presented in Figure S1A shown here, 
gives some hint of such a relationship, but 
parametric correlation tests fall short of 
statistical significance at 5%. Interestingly, 
nonparametric tests (Spearman’s or Kend-
all’s) do reveal ordinal relationships of both 
functional parameters with %GFP but only 
indicate trends within the cell-injected 
muscle series and do not reveal the quan-
titative relationships involved. Certainly, 
the attribution of a 5.5-fold increase in 
muscle strength to cell injection cannot be 
sustained when the sham-injected control 
muscle series is the stronger and contains 
values for both parameters that far exceed 
those for normal control muscle. This high-
lights the main problem with these data: 
the enormous intermuscle variability of the 
functional parameters, especially among 
the controls, generates experimental 
noise that calls into question any detailed 
statistical analysis. Attention has been ecember 12, 2008 ©2008 Elsevier Inc. 997
drawn recently to experimental noise as a 
source of false-positive outcomes (Schna-
bel, 2008). It is possible that the Cerletti et 
al. (2008) study may, likewise, have been 
impacted by the problem of experimental 
noise.
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In his Correspondence, Terence Par-
tridge raises two issues regarding our 
recent study investigating the stem cell 
properties of FACS-purified skeletal 
muscle precursors (SMPs) (Cerletti et al., 
2008). First, he challenges our conclu-
sion that SMPs represent a distinct myo-
genic cell population, and second, he 
questions our physiological assessment 
of the SMP-engrafted muscles of dystro-
phic mdx mice. However, as elaborated 
below, his point regarding the novelty of 
our cell isolation strategy is inaccurate, 
and more importantly, his reanalysis of 
our functional data uses inappropriate 
statistical methods that lead him to an 
erroneous conclusion.
First, Dr. Partridge argues that SMPs 
are not a unique myogenic cell population 
because (1) SMPs share phenotypic mark-
ers with muscle satellite cells, and (2) a pre-
vious publication (Montarras et al., 2005), 
which he coauthored, isolated a similar 
population of cells using gene-targeted 
Pax3-GFP reporter mice and another cell-
surface marker (CD34 expression).
We agree that SMPs have properties 
similar to Pax3-GFP+ muscle satellite cells 
and properly credit this work in our paper 
(Cerletti et al., 2008, p. 42). However, Dr. 
Partridge seems to disregard direct evi-
dence presented in our study that SMPs 
are a distinct subset of muscle satellite 
cells. We showed that most SMPs do 
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express the canonical satellite cell marker 
Pax7, but that SMP markers (β1-integrin 
and CXCR4) are expressed by only ~80% 
of Pax7+ cells. Thus, we conclude that 
SMPs are a subpopulation of satellite 
cells, which unlike Pax3-GFP+ cells (Mon-
tarras et al., 2005) do not require special-
ized transgenic mouse strains for their 
isolation. More importantly, however, our 
work rigorously demonstrates distinctive 
functional and physiological properties 
of SMPs (Cerletti et al., 2008; Sherwood 
et al., 2004), an essential step in the 
effective characterization of any stem or 
progenitor cell population (Wagers and 
Weissman, 2004). In particular, we have 
shown that SMPs are the only subset of 
myofiber-associated cells that exhibits 
clonal myogenesis in vitro and a robust 
myogenic contribution in vivo. Our more 
recent experiments using intramuscular 
transplantation of single GFP+ SMPs fur-
ther demonstrate that ~50% of muscles 
transplanted with a single SMP exhibit 
detectable myofiber engraftment (n = 10 
muscles, M.C. and A.W., unpublished 
data). Given that previous studies indicate 
that 99% of myogenic donor cells per-
ish almost immediately upon transplant 
(Beauchamp et al., 1999), these data 
clearly indicate that selection for SMP 
markers yields a unique, highly purified 
population of cells that is well suited to in 
vivo cell therapy.
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tridge relates to our conclusion that high-
level in vivo engraftment of myofibers by 
donor SMPs results in improved physi-
ological function in recipient muscles. 
His challenge is based largely on the fact 
that we presented our data in a chart that 
correlated muscle engraftment level with 
the fold difference in contractile activity of 
SMP-treated versus mock-treated con-
tralateral muscles in the same animal (see 
Figure 5, Cerletti et al., 2008). We main-
tain that this is an appropriate method of 
analysis because the comparison of SMP-
treated versus mock-treated muscles in 
the same mouse accounts for variability 
in dystrophic disease and in engraftment 
efficiency in individual mdx recipients. In 
fact, clinical trials for myoblast transplan-
tation and for exon skipping use similar 
comparisons to assess treatment efficacy 
(http://www.clinicaltrials.gov/, reviewed 
in Cossu and Sampaolesi, 2007). In any 
case, we also provided the same data in 
raw form in the Supplemental Data of our 
paper (Table S1). 
Using the data in our Table S1 (Cerletti 
et al., 2008), Dr. Partridge has reanalyzed 
our results and comes to the conclusion 
that the only reason our SMP-treated 
muscles showed improvement is that 
they were compared to contralateral 
muscles that were particularly weak. This 
conclusion is based on replotting of our 
data using a linear regression model and 
on parametric correlation tests, which 
Dr. Partridge states “fall short of statisti-
cal significance at 5%” (in fact, the actual 
values are p = 0.055 and p = 0.056, using 
Pearson’s product-moment correlation, 
for the specific peak force and the inte-
grated area under the curve, respec-
